摘要
目的观察高血压性心脏病患者应用酒石酸美托洛尔片(商品名:倍他乐克)治疗的临床疗效。方法80例高血压性心脏病患者,采用随机数字表法分为参照组和研究组,每组40例。参照组给予厄贝沙坦治疗,研究组在参照组基础上给予倍他乐克治疗。对比两组患者的治疗效果、血压指标、心功能指标、临床症状评分。结果研究组患者的治疗总有效率97.50%高于参照组的80.00%(P<0.05)。治疗后,两组患者的收缩压、舒张压均低于本组治疗前,且研究组患者的收缩压(98.56±8.75)mm Hg(1 mm Hg=0.133 kPa)、舒张压(81.52±6.42)mm Hg低于参照组的(119.89±6.98)、(98.36±6.78)mm Hg(P<0.05)。治疗后,两组患者的左室射血分数、每搏输出量、心输出量均高于本组治疗前,且研究组患者的左室射血分数(63.23±5.12)%、每搏输出量(73.69±8.12)ml、心输出量(5.66±0.89)L/min高于参照组的(52.45±4.81)%、(62.45±7.36)ml、(4.80±1.65)L/min(P<0.05)。治疗后,两组患者的乏力、心悸、胸闷、气短评分均低于本组治疗前,且研究组患者的乏力评分(0.40±0.11)分、心悸评分(0.39±0.05)分、胸闷评分(0.25±0.08)分、气短评分(0.35±0.12)分均低于参照组的(1.39±0.23)、(1.44±0.19)、(1.08±0.15)、(1.44±0.23)分(P<0.05)。结论高血压性心脏病给予倍他乐克治疗可以有效增强疗效,降低血压,改善心功能、临床症状,值得借鉴。
Objective To observe the clinical efficacy of metoprolol tartrate tablets(trade name:Betaloc)on patients with hypertensive heart disease.Methods A total of 80 patients with hypertensive heart disease were divided into reference group and study group according to random number table method,with 40 cases in each group.The reference group was given irbesartan treatment,and the study group was given Betaroc treatment on the basis of reference group.The therapeutic effect,blood pressure indexes,cardiac function indexes,and clinical symptom score of the two groups were compared.Results The total effective rate of 97.50%in the study group was higher than 80.00%in the reference group(P<0.05).After treatment,the systolic and diastolic blood pressure in both groups were lower than those before treatment;in the study group,the systolic blood pressure was(98.56±8.75)mm Hg(1 mm Hg=0.133 kPa)and the diastolic blood pressure was(81.52±6.42)mm Hg,which were lower than(119.89±6.98)and(98.36±6.78)mm Hg in the reference group(P<0.05).After treatment,the left ventricular ejection fraction,stroke volume and cardiac output in both groups were higher than those before treatment;in the study group,the left ventricular ejection fraction was(63.23±5.12)%,the stroke volume was(73.69±8.12)ml,and the cardiac output was(5.66±0.89)L/min,which were higher than(52.45±4.81)%,(62.45±7.36)ml,and(4.80±1.65)L/min in the reference group(P<0.05).After treatment,the scores of fatigue,palpitation,chest tightness and shortness of breath in both groups were lower than those before treatment;the scores of fatigue,palpitation,chest tightness and shortness of breath in the study group were(0.40±0.11),(0.39±0.05),(0.25±0.08)and(0.35±0.12)points,which were lower than(1.39±0.23),(1.44±0.19),(1.08±0.15)and(1.44±0.23)points in the reference group(P<0.05).Conclusion Betaloc can effectively enhance the therapeutic effect,reduce blood pressure and improve cardiac function in patients with hypertensive heart disease,and is worthy of reference.
作者
张秋香
段艳平
ZHANG Qiu-xiang;DUAN Yan-ping(Jinxiang County People's Hospital,Jining 272200,China)
出处
《中国实用医药》
2025年第10期6-10,共5页
China Practical Medicine
关键词
高血压性心脏病
酒石酸美托洛尔片
血压
心功能指标
Hypertensive heart disease
Metoprolol tartrate tablets
Blood pressure
Cardiac function indicators
